FindTrial
Sign In

Phase II multicenter study of association of arsenic trioxide (ATO) and ascorbic acid in myelodisplastic syndromes

Phase II multicenter study of association of arsenic trioxide (ATO) and ascorbic acid in myelodisplastic syndromes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-001321-28-IT
Enrollment
Unknown
Registered
2005-06-07
Start date
2005-06-13
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodisplastyc Syndrome treatment MedDRA version: 6.1 Level: HLT Classification code 10028536

Interventions

Trade Name: TRISENOX Pharmaceutical Form: Emulsion for infusion INN or Proposed INN: Arsenic trioxide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .3-

Sponsors

AISSM ONLUS
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026